Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ACTH silent adenoma shrinking under cabergoline.

P Petrossians1, N Ronci, H Valdés Socin

  • 1Endocrinology, CHU Sart Tilman, Liège, Belgium.

European Journal of Endocrinology
|February 15, 2001
PubMed
Summary

Cabergoline treatment led to shrinkage of a silent ACTH adenoma. In vitro studies confirmed dopamine D2 receptors in the tumor, suggesting cabergoline may treat recurrent silent ACTH adenomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.

Journal of endocrinological investigation·2024
Same author

Non-invasive assessment of muscle compartment elasticity by pressure-related ultrasound in pediatric trauma: a prospective clinical study in 25 cases of forearm shaft fractures.

European journal of medical research·2023
Same author

[How to explore... hyperandrogenism associated with insulin resistance ? An example based on the HAIR-AN syndrome.]

Revue medicale de Liege·2021
Same author

An Infundibular Unidentified Object (IUO): a new pituitary stalk marker?

Pituitary·2021
Same author

[Neuroendocrine neoplasms : a new era to the top of multidisciplinarity !]

Revue medicale de Liege·2021
Same author

[Chronic pheochromocytoma-induced myocardial injuries: What should we expect from modern and classical echocardiographic tools?]

Annales de cardiologie et d'angeiologie·2020

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Silent ACTH adenomas are rare pituitary tumors.
  • Clinically non-functioning pituitary adenomas present a diagnostic challenge.
  • Effective treatments for recurrent silent ACTH adenomas are limited.

Observation:

  • A 77-year-old patient with recurrent silent ACTH adenoma showed clinical and radiological improvement with cabergoline treatment.
  • In vitro studies of the patient's tumor revealed intense dopamine D2 receptor mRNA.
  • Dopamine D2 receptor autoradiography of the tumor was significantly higher than control corticotroph adenomas.

Findings:

  • This is the first report of in vivo tumor shrinkage of a silent ACTH adenoma using cabergoline.
  • The tumor expressed dopamine D2 receptors at concentrations comparable to prolactinomas.

Related Experiment Videos

  • Cabergoline's efficacy is linked to the presence of D2 receptors in silent ACTH adenomas.

    • Implications:

    • Cabergoline may be a viable therapeutic option for recurrent silent ACTH adenomas.
    • Dopamine D2 receptor expression is a potential predictive marker for cabergoline response.
    • Further clinical trials are warranted to evaluate cabergoline for non-functioning pituitary adenomas.